Liraglutide (Victoza®) Post-Marketing Surveillance Initiated to Assess Real-World Safety and Effectiveness

Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disorder requiring ongoing management, often involving combination therapies. While GLP-1 receptor agonists like liraglutide are well-established, real-world data is crucial to confirm long-term safety and effectiveness in diverse populations and specific treatment regimens. This study addresses the need for such post-marketing surveillance data on liraglutide in Asian T2DM patients, particularly when combined with antidiabetic agents other than sulfonylureas, to identify any nuances not captured in initial clinical trials.

This post-marketing surveillance (Special Use-results Surveillance) trial is conducted in Asia, evaluating Liraglutide (Victoza®). The study aims to assess safety and effectiveness in type 2 diabetes mellitus (T2DM) patients. Participants are using liraglutide in combination with antidiabetes agents other than sulfonylurea under normal clinical practice conditions. Data is collected observationally, focusing on real-world outcomes. The primary endpoints are the overall safety profile and clinical effectiveness of liraglutide in this specific patient cohort.